Alveolar soft part sarcoma (ASPS) is a rare, indolent soft tissue sarcoma, with a high predilection for systemic dissemination. This study aims at elucidating the patterns of clinical presentation of ASPS and their treatment outcomes, with emphasis on the efficacy of anti-angiogenesis agents, and the challenges faced in managing these rare tumours in low and middle-income countries (LMICs).